ena-STUDY-Danish Cancer Society-24-01-2020-14:22:19:654-151
Supplementary Sequence Files Whole genome sequencing of bladder cancer cell lines
KU19-19 and RT4 are bladder cancer cell lines with no known ERCC2 mutation, while KE1 is a derivative of the KU19-19 line that harbors an inactivating ERCC2 mutation introduced by CRISPR/Cas9 gene editing.
KU19-19 and RT4 are bladder cancer cell lines with no known ERCC2 mutation, while KE1 is a derivative of the KU19-19 line that harbors an inactivating ERCC2 mutation introduced by CRISPR/Cas9 gene editing.